Detection of Microsatellite Instability via Circulating Tumor DNA and Response to Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: A Case Series

Pembrolizumab has been approved by the US Food and Drug Administration for the treatment of metastatic or unresectable solid tumors that are microsatellite instability-high (MSI-H) or mismatch repair deficient. Blood-based circulating tumor DNA (ctDNA) assays have been validated to identify tumors w...

Descripción completa

Detalles Bibliográficos
Autores principales: Ravindranathan, Deepak, Russler, Greta Anne, Yantorni, Lauren, Drusbosky, Leylah M., Bilen, Mehmet Asim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983538/
https://www.ncbi.nlm.nih.gov/pubmed/33776702
http://dx.doi.org/10.1159/000512819

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983538/
https://www.ncbi.nlm.nih.gov/pubmed/33776702
http://dx.doi.org/10.1159/000512819

Ejemplares similares